Neoplasma Vol.52, p.182-184, 2005
|
Title: Endostatin serum level in acute myeloid leukemia
|
Author: T., WROBEL
; G., MAZUR
; K., KAPELKO
; K., KULICZKOWSKI
; |
|
Abstract: Increased levels of tumor angiogenesis have been demonstrated in
variety of solid tumors and hematological malignancies including
acute myeloid leukemia (AML). The aim of the study was to evaluate
serum level of endostatin in newly diagnosed patients with AML
before chemotherapy and after achieving complete remission (CR).
Serum samples from 68 adult patients (28 females and 40 males,
median age 42 years, range 21–83 years) with AML had been taken
before chemotherapy was administered. In addition 21 out of 68
patient were analyzed again after achieving CR. Endostatin levels
were measured using ChemiKine sandwich ELISA kit (Chemicon
International). Twelve samples from healthy volunteers (5 females
and 7 males, median age 40 years; range 35–65 years) were
evaluated as the control. Endostatin serum levels were
significantly higher in untreated AML patients than in the normal
controls. In AML patients baseline endostatin levels were
significantly lower than in CR. We did not found any correlation
between white cell count or percentage of blasts in the bone
marrow and endostatin level. Moreover endostatin levels did not
differ statistically among AML FAB subgroups. Increased endostatin
plasma levels may reflect intensity of inhibition of angiogenesis
and may by useful in prognosis of CR in AML. Chemotherapy can
modulate the regulation of angiogenesis in AML patients.
|
|
Keywords: endostatin, angiogenesis, acute myeloid leukemia
|
Year: 2005, Volume: 52, Issue: |
Page From: 182, Page To: 184 |
|
|
|
|
download file |
|
|
|
|